KLH

Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX
VENTURE: KLH) announced today the launch of its corporate video highlighting the
Company's business of manufacturing Keyhole Limpet Hemocyanin (KLH) protein. KLH
is an immune-stimulating molecule widely used in the growing field of
immunotherapy.


The video is available for viewing on Stellar's website at:
www.stellarbiotechnologies.com/media/videos


The corporate video provides an overview of Stellar's commercial position in
immunotherapy development. It includes interviews with Company executives and
was filmed at Stellar's California-based aquaculture research and production
facilities where Stellar KLH(TM) protein is manufactured for use as a vaccine
carrier molecule or for immunotoxicology applications.


"We have a dedicated team of scientists and personnel working in a unique
environment that combines pharmaceutical manufacturing and marine technologies,"
said Frank Oakes, President and CEO of Stellar. "We are pleased to give viewers
this glimpse at our pioneering work in scalable manufacture of sustainable GMP
grade KLH."


About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSX VENTURE: KLH) is the leader in
sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important
immune-stimulating protein used in wide-ranging therapeutic and diagnostic
markets. KLH is both an active pharmaceutical ingredient (API) in many new
immunotherapies (targeting cancer, infectious diseases, and immune disorders) as
well as a finished product for measuring immune status. Stellar Biotechnologies
is unique in its proprietary methods, facilities, and KLH technology. We are
committed to meeting the growing demand for commercial-scale supplies of GMP
grade KLH, ensuring environmentally sound KLH production, and developing
KLH-based active immunotherapies.


Visit www.StellarBiotech.com and the KLH knowledge base www.KLHSite.org.

Forward Looking Statements
This press release may contain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking statements may be
identified by the use of words such as "anticipate," "believe," "plan,"
"estimate," "expect," "intend," "may," "will," "would," "could," "should,"
"might," "potential," or "continue" and variations or similar expressions.
Readers should not unduly rely on these forward-looking statements, which are
not a guarantee of future performance. There can be no assurance that
forward-looking statements will prove to be accurate, as all such
forward-looking statements involve known and unknown risks, uncertainties and
other factors which may cause actual results or future events to differ
materially from the forward-looking statements. Such risks include, but may not
be limited to: general economic and business conditions; technology changes;
competition; changes in strategy or development plans; governmental regulations
and the ability or failure to comply with governmental regulations; the timing
of anticipated results; and other factors referenced in the Company's filings
with securities regulators. For a discussion of further risks and uncertainties
related to the Company's business, please refer to the Company's public company
reports filed with the TSX Venture Exchange and the U.S. Securities and Exchange
Commission. All forward-looking statements are made as of the date hereof and
are subject to change. Except as required by law, the Company assumes no
obligation to update such statements. This press release does not constitute an
offer or solicitation of an offer for sale of any securities in any
jurisdiction, including the United States. Neither the TSX Venture Exchange nor
its Regulation Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the
information contained in this press release.




FOR FURTHER INFORMATION PLEASE CONTACT: 
Frank Oakes
President and CEO
Phone +1 (805) 488-2800
IR@stellarbiotech.com


Mark McPartland
Vice President of Corporate Development and Communications
Phone: +1 (805) 488-2800 ext. 103
markmcp@stellarbiotech.com
www.stellarbiotech.com

Stellar Biotechnologies, Inc. (TSXV:KLH)
Historical Stock Chart
From May 2024 to Jun 2024

Stellar Biotechnologies, Inc. (TSXV:KLH)
Historical Stock Chart
From Jun 2023 to Jun 2024